76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
MediciNova Inc
Open
SectorHealthcare
1.27 -2.31
Overview
Share price change
24h
Min
1.27
Max
1.33
Income | -49K -2.9M |
|---|---|
EPS | -0.06 |
Employees | 13 |
EBITDA | -19K -3.2M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +267.65% upside |
Next Earnings | 6 Aug 2025 |
|---|
Market Cap | -6.4M 64M |
|---|---|
Previous open | 3.58 |
Previous close | 1.27 |
News Sentiment
By Acuity
50%
50%
165 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
MediciNova Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
MediciNova Inc Forecast
Price Target
By TipRanks
267.65% upside
12 Months Forecast
Average 5 USD 267.65%
High 5 USD
Low 5 USD
Based on 1 Wall Street analysts offering 12 month price targets forMediciNova Inc - Dist in the last 3 months.
Sentiment
By Acuity
165 / 380 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
